Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge - Top-Institutions - MDSpire

Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge

  • By

  • Jamila Raja

  • Shuo Li

  • Asal Patterson

  • Steve R. Martinez

  • Perry A. Soriano

  • Xiaowen Wang

  • Peter Y. Z. Jiang

  • July 16, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #2

    Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
    Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, NY

    Key Differentiators

    • Oncology

  • #3

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #4

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, FL

    Key Differentiators

    • Oncology

  • #5

    Center for Cancer Immune Therapy, Herlev Hospital
    Center for Cancer Immune Therapy, Herlev Hospital

    Herlev, Denmark

    Key Differentiators

    • Oncology

Original Source(s)

Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge

  • by Jamila Raja, Shuo Li, Asal Patterson, Steve R. Martinez, Perry A. Soriano, Xiaowen Wang, Peter Y. Z. Jiang

  • July 16, 2026

Related Content

Locus-specific HERV expression identifies an aggressive, NK-depleted, checkpoint-refractory acral melanoma phenotype

The role and signal pathways of opsin 3 in the skin: from light perception to pathophysiological mechanisms

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer